Developing novel therapeutics to restore brain functions in neurodegenerative diseases

About Us

Teitur develops novel therapeutics for treating or preventing neurodegenerative diseases.

Teitur is Old Norse for happiness. Our ambition and commitment is to create new treatments for patients suffering from neurodegenerative diseases to help them live a longer, better and happier life.

From the Sortilins family of receptors, Teitur has developed cyclic peptides with a unique potential for addressing key pathologies across several neurodegenerative disorders including Huntington’s Disease, Parkinson’s Disease and Frontotemporal Dementia. These diseases impact memory, behaviour, movement and mood of millions of people around the globe and Teitur strive to improve the lives of these patients.

Our Focus

More than 200 million patients suffer from neurodegenerative disorders world-wide. Today, no treatments are available to prevent the relentless progression of neurodegeneration, affecting memory, movement and quality of life for them and their loved ones.

Teitur is dedicated to develop novel compounds that can address this unmet medical need and provide true disease modifying opportunities to improve the lives of patients.

Our Team

Our team is comprised of innovative scientific founders and is supported by seasoned veterans within neurology, drug discovery and pharmaceuticals and world-class experts within Huntington’s Disease.

Latest News

Teitur Trophics Raises EUR 28M in Series A Financing to Advance the Development and Treatment for Neurodegenerative Diseases

  • Financing co-led by Sunstone Life Science Ventures and Sound Bioventures with participation from Industrifonden, Innovestor’s Life Science Fund and P53 Invest
  • Discovery of a novel mechanism with the potential to prevent the death of neurons in neurodegenerative diseases
  • First-in-Class, lead drug candidate advances into clinical development in a Phase 1b study
  Aarhus, Denmark March 14th, 2023: Teitur Trophics (“Teitur”), a biotech company dedicated to developing new treatments for patients suffering from neurodegenerative diseases, today announces the completion of a €28M Series A financing. The…
Read more